Evidence map›Paper›PMID 26360778›Full record

ArticleOncotarget2015

Pre-transplant weight loss predicts inferior outcome after allogeneic stem cell transplantation in patients with myelodysplastic syndrome.

Aleksandar Radujkovic, Natalia Becker, Axel Benner, Olaf Penack, Uwe Platzbecker, Friedrich Stölzel, Martin Bornhäuser, Ute Hegenbart, Anthony D Ho, Peter Dreger and 1 more

Open access · diamondAbstract readMulticenter Study
In one paragraph

Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Weight loss post-allogeneic stem cell transplant is associated with increased transplant-related mortality.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Aleksandar RadujkovicDepartment of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
Natalia BeckerDivision of Biostatistics, German Cancer Research Center, Heidelberg, Germany.
Axel BennerDivision of Biostatistics, German Cancer Research Center, Heidelberg, Germany.
Olaf PenackCampus Benjamin Franklin, Charité, Interdisziplinäre Klinik und Poliklinik für Stammzelltransplantation, Berlin, Germany.
Uwe PlatzbeckerDepartment of Internal Medicine I, University Hospital Carl Gustav Carus Dresden, Technical University Dresden, Dresden, Germany.
Friedrich StölzelDepartment of Internal Medicine I, University Hospital Carl Gustav Carus Dresden, Technical University Dresden, Dresden, Germany.
Martin BornhäuserDepartment of Internal Medicine I, University Hospital Carl Gustav Carus Dresden, Technical University Dresden, Dresden, Germany.
Ute HegenbartDepartment of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
Anthony D HoDepartment of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
Peter DregerDepartment of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
Thomas LuftDepartment of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
University Hospital Heidelberg · DEUniversity Hospital Carl Gustav Carus · DEGerman Cancer Research Center · DECharité - Universitätsmedizin Berlin · DEHeidelberg University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Allogeneic stem cell transplantation (alloSCT) represents a curative therapeutic option for patients with myelodysplastic syndrome (MDS), but relapse and non-relapse mortality (NRM) limit treatment efficacy. Based on our previous observation in acute myeloid leukemia we investigated the impact of pre-transplant weight loss on post-transplant outcome in MDS patients. A total of 111 patients diagnosed with MDS according to WHO criteria transplanted between 2000 and 2012 in three different transplant centers were included into the analysis. Data on weight loss were collected from medical records prior to conditioning therapy and 3-6 months earlier. Patient, disease and transplant characteristics did not differ between patients with weight loss (2-5%, n = 17; > 5%, n = 17) and those without (n = 77). In a mixed effect model, weight loss was associated with higher risk MDS (p = 0.046). In multivariable analyses, pre-transplant weight loss exceeding 5% was associated with a higher incidence of relapse (p < 0.001) and NRM (p = 0.007). Pre-transplant weight loss of 2-5% and > 5% were independent predictors of worse disease-free (p = 0.023 and p < 0.001, respectively) and overall survival (p = 0.043 and p < 0.001, respectively). Our retrospective study suggests that MDS patients losing weight prior to alloSCT have an inferior outcome after transplantation. Prospective studies addressing pre-transplant nutritional interventions are highly warranted.

Indexed as

Hematopoietic Stem Cell TransplantationWeight LossAdultAgedAllograftsFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMyelodysplastic SyndromesPrognosisRetrospective StudiesRisk FactorsTreatment OutcomeYoung Adultallogeneic stem cell transplantationMDSoutcomerelapseweight loss

Identifiers

PMID26360778
PMCPMC4741512
OpenAlexW2173015420

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.